* 中国生物科技公司--康宁杰瑞制药9966.HK周四早盘一度升4.5%，早市收高2.6%。
* 该公司此前公告称，JSKN003已获美国食品药品监督管理局（FDA）授予突破性疗法认定，用于治疗既往接受过贝伐珠单抗治疗的晚期或转移性人表皮生长因子受体2有表达铂耐药复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌成年患者。
* 康宁杰瑞制药今年迄今暴涨200%，同期恒生指数.HSI上扬26.4%。
* 恒⽣⽣物科技指数.HSBIO早市收高0.7%（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 吴云凌)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.